Effects of simvastatin on the pharmacokinetics of verapamil and its main metabolite, norverapamil, in rats

European Journal of Drug Metabolism and Pharmacokinetics

Volumn 34, Issue 3-4, 2009, Pages 163-168

  Choi, Dong Hyun ^a   Li, Cheng ^a,b   Choi, Jun Shik ^a  

^a Chosun University   (South Korea)

^b YANBIAN UNIVERSITY   (China)

Author keywords

CYP3A4; Norverapamil; P gp; Pharmacokinetic; Rat; Simvastatin; Verapamil

Indexed keywords

CYTOCHROME P450 3A; GLYCOPROTEIN P; NORVERAPAMIL; SIMVASTATIN; VERAPAMIL;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG HALF LIFE; DRUG METABOLISM; ENZYME INHIBITION; HUMAN; HUMAN CELL; LIVER; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PLASMA CONCENTRATION-TIME CURVE; RAT; SMALL INTESTINE; TIME TO MAXIMUM PLASMA CONCENTRATION;

EID: 72149099860     PISSN: 03787966     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03191168     Document Type: Article

References (19)

1. Fleckenstein A., (1977): Specific pharmacology of calcium in myocardium, cardiac pacemakers, and vascular smooth muscle. Ann. Rev. Pharmacol. Toxicol., 17, 149-166.
2. Gould B.A., Mann S., Kieso H., Bala Subramanian V., Raftery E.B. (1982): The 24-hour ambulatory blood pressure profile with verapamil. Circulation, 56, 22-27. (Pubitemid 12250885)
3. Lewis G.R., Morley K.D., Lewis B.M., Bones P.J. (1978): The treatment of hypertension with verapamil. NZ. Medical J., 87, 351-354.
4. Schomerus M., Spiegelhaider B., Stieren B., Eichelbaum M., (1976): Physiologic disposition of verapamil in man. Cardiovasc. Res., 10, 605-612.
5. Eichelbaum, M., Remberg, E. G., Schomerus, M., Dengler, H. J. (1979): The metabolism of D,L(14C) verapamil in man. Drug Metab. Dispos., 7, 145-148.
6. Eichelbaum M., Mikus G., Vogelgesang B. (1984): Pharmacokinetics of (+)-, (-)- and (±)-verapamil after intravenous administration. Brit. J. Clin. Pharmacol., 17, 453-458.
7. Adachi Y., Suzuki H., Sugiyama Y., (2001): Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm. Res., 18, 1660-1668.
8. Doppenschmitt S., Spahn-Langguth H., Regardh C.G., Lang-guth P., (1999): Role of P-glycoprotein-mediated secretion in absorptive drug permeability: An approach using passive membrane permeability and affinity to P-glycoprotein. J. Pharm. Sci., 88, 1067-1072.
9. Gottesman M.M., Pastan I., (1993): Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu. Rev. Biochem., 62, 385-427.
10. Prueksaritanont T., Gorham L.M., Ma B., (1997): In vitro metabolism of simvastatin in humans: identification of metabolizing enzymes and effect of the drug on hepatic P450s. Drug Metab. Dispos., 25, 1191-1199.
11. FDA Guidance for industry: In vivo drug metabolism/drug interaction studies-study design, data analysis, and recommendations for dosing and labeling. [cited November 24, 1999] http://www.fda.gov/cder/guidance/index.htm
12. Wang E., Casciano C.N., Clement R.P., Johnson W.W., (2001): HMG-CoA reductase inhibitors (statins) characterized as direct inhibitors of P-glycoprotein. Pharm. Res., 18, 800-806.
13. Bogman K., Peyer A.K., Torok M., Kusters E., Drewe J., (2001): HMG-CoA reductase inhibitors and P-glycoprotein modulation. Br. J. Pharmacol., 132, 1183-1192.
14. Wacher V.J., Salphati L., Benet L.Z., (1996): Active secretion and enterocytic drug metabolism barriers to drug absorption. Adv. Drug Deliver. Rev., 20, 99-112.
15. Benet L.Z., Cummins C.L., Wu C.Y., (2003): Transporter-enzyme interactions: implications for predicting drug-drug interactions from in vitro data. Curr. Drug Metab., 4, 393-398.
16. Cummins C.L., Jacobsen W., Benet L.Z., (2002): Unmasking the dynamic interplay between intestinal P-glycoprotein and CYP3A4. J. Pharmacol. Exp. Ther., 300, 1036-1045.
17. Marumo H., Satoh K., Yamamoto A., Kaneta S., Ichihara K., (2001): Simvastatin and atorvastatin enhance hypotensive effect of diltiazem in rats. Yakugaku Zasshi., 121, 761-764. (Pubitemid 33021587)
18. Bottorff M.B., (2006): Statin safety and drug interactions: clinical implications. Am. J. Cardiol., 17, 27-31.
19. Choi J.S., Han H.K., (2004): The effect of quercetin on the pharmacokinetics of verapamil and its major metabolite, norverapamil, in rabbits. J. Pharm. Pharmacol., 56, 1537-1542.